IL17A and psoriasis: In three ixekizumab trials in psoriasis, depression remitted in up to 45% of comorbid patients following IL-17A treatment, however mood improvement was only weakly associated with CRP reduction (r = 0.11, p < 0.001) (Griffiths et al., 2017).